Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.

Achieve Life Sciences Inc.

Achieve Life Sciences ( ($ACHV) ) has released its Q3 earnings. Here is a breakdown of the information Achieve Life Sciences presented to its inves...

Achieve Life Sciences Reports Q3 2025 Results

Achieve Life Sciences (($ACHV)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Achieve Li...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACHV	$3.96	+2.06%	434.24K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACHV	$3.96	+2.1%	434.24K
3
4
5
6

ACHV

ACHV

Dividend Overview

Get Achieve Life Sciences Inc. Data in Excel

Get Achieve Life Sciences Inc. Data in Excel